Restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products
First written in FY2016. 25 of 26 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2026: 4 of 9 companies on the "Worse" side.
13 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「If these regulations cannot be complied with, the activities of the Company and its consolidated subsidiaries may be restricted.」
The regulations concerning permits, licenses, registrations and notifications for pharmaceuticals, medical devices and other products, as well as the risk of restricted activities if they are not complied with, continue to apply. - FY2025-H1RestatedAnnual report
「The filing states that, during the interim consolidated accounting period, there were no material changes in the major risks that management recognizes could materially affect the consolidated companies' financial position, operating results or cash flows, or in the matters described under Business Risks in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning the risk of restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning the risk of restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2024-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning the risk of restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2022RestatedAnnual report
「If these regulations cannot be complied with, the activities of the Company and its consolidated subsidiaries may be restricted.」
The regulations concerning permits, licenses, registrations and notifications for pharmaceuticals, medical devices and other products, as well as the risk of restricted activities if they are not complied with, continue to be disclosed. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing states that there have been no material changes concerning the risk of restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2022-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
The filing states that there have been no material changes concerning the risk of restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2021RestatedAnnual report
「If these regulations cannot be complied with, the Group's activities may be restricted.」
The legal regulations concerning permits, licenses, registrations and notifications for pharmaceuticals, medical devices and other products, as well as the risk of restricted activities if they are not complied with, continue to be disclosed. - FY2021-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning the risk of restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing states that there have been no material changes concerning the risk of restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2020RestatedAnnual report
「If these regulations cannot be complied with, the Group's activities may be restricted.」
The legal regulations concerning permits, licenses, registrations and notifications for pharmaceuticals, medical devices and other products, as well as the risk of restricted activities if they are not complied with, continue to be disclosed. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2020-Q1RestatedAnnual report
「During the first three months of the consolidated fiscal year, there were no material changes concerning matters described in the quarterly securities report that could materially affect investors' decisions, or to the business and other risks described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2019RestatedAnnual report
「The Group operates as a pharmaceutical wholesaler, handling various pharmaceuticals and related products. Accordingly, primarily under the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc., each business location conducts sales activities after obtaining the necessary permits, registrations, designations and licenses from the relevant prefectural governor, or after filing notifications with the relevant government authorities. If these regulations cannot be complied with, the Group's activities may be restricted.」
The annual report explicitly identifies the regulations concerning permits, licenses, registrations and notifications for pharmaceuticals, medical devices and other products, as well as the risk of restricted activities if they are not complied with. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2019-Q1RestatedAnnual report
「During the first three months of the consolidated fiscal year, there were no material changes concerning matters described in the quarterly securities report that could materially affect investors' decisions, or to the business and other risks described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2018RestatedAnnual report
「If these regulations cannot be complied with, the Group's activities may be restricted.」
The annual report explicitly identifies the legal regulations concerning permits, licenses, registrations and notifications for pharmaceuticals, medical devices and other products, as well as the risk of restricted activities if they are not complied with. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2018-Q1RestatedAnnual report
「During the first three months of the consolidated fiscal year, there were no material changes concerning matters described in the quarterly securities report that could materially affect investors' decisions, or to the business and other risks described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2017RestatedAnnual report
「The Group operates as a pharmaceutical wholesaler, handling various pharmaceuticals and related products. Accordingly, primarily under the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc., each business location conducts sales activities after obtaining the necessary permits, registrations, designations and licenses from the relevant prefectural governor, or after filing notifications with the relevant government authorities. If these regulations cannot be complied with, the Group's activities may be restricted.」
The annual report explicitly identifies the regulations concerning permits, licenses, registrations and notifications for pharmaceuticals, medical devices and other products, as well as the risk of restricted activities if they are not complied with. - FY2017-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing states that there have been no material changes from the risks described in the previous fiscal year concerning restrictions on business activities due to violations of laws and regulations governing pharmaceuticals, medical devices and other products. - FY2016First statedAnnual report
「The Group operates as a pharmaceutical wholesaler, handling various pharmaceuticals and related products. Accordingly, primarily under the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc., each business location conducts sales activities after obtaining the necessary permits, registrations, designations and licenses from the relevant prefectural governor, or after filing notifications with the relevant government authorities. If these regulations cannot be complied with, the Group's activities may be restricted.」
The filing describes the risk that activities may be restricted if the Group fails to comply with regulations concerning permits, licenses, registrations and notifications associated with the pharmaceutical wholesale business.